Lupin settles patent infringement dispute with Astellas, to continue selling overactive bladder drug Mirabegron
Under the agreement, Lupin will pay Astellas $90 million, which includes a prepaid option payment of $75 million, and a prepaid per unit license fee for each unit of its product sold through September 2027